Intelligence · Clinical Development
Pipeline search results
Programs matching “air” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 160 pipeline programs matching "air" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
UC-0140/1812
Ningbo Cancer Hospital
ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.
1 trial -
Valbenazine Oral Capsule
NEUROCRINE BIOSCIENCES INC
Trichotillomania (Hair-Pulling Disorder)
1 trial -
donepezil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cognitive Impairment
1 trial -
0352-2189
Boehringer Ingelheim
1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B
1 trial -
0352-2190
Boehringer Ingelheim
1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B
1 trial -
100 mg Resmetirom Tablet
Madrigal Pharmaceuticals EU Limited
Renal Impairment
1 trial -
1404-0009
Boehringer Ingelheim
Renal impairment (mild, moderate and severe), Healthy
1 trial -
145 mg/m2 NKTR 102
Nektar Therapeutics UK Limited
Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
1 trial -
20250004
Amgen
microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors
1 trial -
22534
Bayer AG
Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.
1 trial -
77242113PSO1007
Janssen-Cilag International N.V.
Renal Impairment
1 trial -
ABT-493
AbbVie
Hepatic Impairment
1 trial -
AG-120 (Ivosidenib)
Agios Netherlands B.V.
Hepatic Impairment
1 trial -
AIR DNase
Protalix BioTherapeutics
Cystic Fibrosis (CF)
1 trial -
AMO-02-MD-1-001
Lacuna Pharma Pty Ltd
Hepatic impairment, Healthy subjects
1 trial -
Airway Bypass
CATALYST PHARMACEUTICALS, INC.
Emphysema or COPD
1 trial -
Aramchol free acid tablet 600mg, single dose
Galmed Pharmaceuticals
Hepatic Impairment
1 trial -
CDAK539A12103
Novartis Pharmaceuticals
Advanced Malignancies and Hepatic Impairment
1 trial -
CEP-26401
Teva Pharma GmbH
Cognitive Impairment
1 trial -
CMX001
Jazz Pharmaceuticals Ireland Limited
Hepatic Impairment
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Cognitive Impairment
1 trial -
D8330C00004
AstraZeneca AB
Heart failure with reduced ejection fraction, Renal impairment
1 trial -
D9090C00007
AstraZeneca AB
Moderate Renal Impairment, Heart Failure
1 trial -
D9090C00010
AstraZeneca AB
Impaired renal function
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.